develop
novel
broadspectrum
antivir
agent
infect
urgent
need
studi
evalu
immunomodulatori
activ
protect
effect
eupatorium
adenophorum
polysaccharid
eap
highli
pathogen
subtyp
influenza
viru
eap
treatment
significantli
increas
product
tnf
ifnboth
vivo
vitro
measur
qpcr
elisa
mous
infect
model
intranas
administr
eap
dose
mgkg
bodi
weight
prior
viral
challeng
effici
inhibit
viral
replic
decreas
lung
lesion
increas
surviv
rate
evalu
innat
immun
recognit
eap
process
regul
primarili
mannos
receptor
mr
result
indic
eap
may
immunomodulatori
properti
potenti
prophylact
effect
influenza
infect
investig
suggest
altern
strategi
develop
novel
antiinfluenza
agent
benefit
e
adenophorum
product
highli
pathogen
subtyp
influenza
viru
transmit
directli
poultri
human
caus
acut
respiratori
infect
pandem
influenza
viru
pose
worldwid
threat
public
health
rapid
spread
high
pathogen
symptom
anim
human
infect
includ
fever
enceph
pneumonia
sever
acut
respiratori
syndrom
sar
world
health
organ
report
human
case
highli
pathogen
influenza
viru
infect
includ
death
mortal
rate
http
wwwwhoint
influenzahuman
anim
cumul
tabl
archivesenindexhtml
current
effect
prevent
measur
influenza
viru
vaccin
sever
antiinfluenza
medic
wide
use
includ
zanamivir
relenza
oseltamivir
tamiflu
unfortun
benefit
significantli
restrict
drugresist
frequent
antigen
mutat
therefor
develop
novel
antiinfluenza
agent
subtyp
import
invas
plant
eupatorium
adenophorum
nativ
central
america
strong
abil
adapt
differ
environ
world
plant
first
invad
southern
yunnan
provinc
china
burma
vietnam
quickli
spread
across
southwestern
china
throughout
past
year
e
adenophorum
serious
impact
ecolog
environ
china
middl
subtrop
zone
includ
yunnan
guizhou
sichuan
guangxi
provinc
encroach
farmland
pastur
field
forest
manual
chemic
biolog
control
e
adenophorum
hinder
comprehens
develop
util
econom
benefit
mani
bioactiv
compon
isol
e
adenophorum
shown
antimicrobi
activ
immunomodul
evidencebas
complementari
altern
medicin
properti
recent
studi
antiinflammatori
properti
ethanol
leaf
extract
evalu
howev
report
address
bioactiv
e
adenophorum
polysaccharid
eap
immunomodul
properti
therapeut
potenti
larg
number
botan
polysaccharid
report
sever
polysaccharid
cordycep
militari
portulaca
oleracea
gracilaria
lemaneiformi
gyrodinium
impudium
panax
ginseng
describ
efficaci
antiinfluenza
agent
strain
recent
report
polysaccharidebas
adjuv
enhanc
immunogen
improv
protect
efficaci
vaccin
anim
infect
model
howev
knowledg
report
regard
treatment
eap
highli
pathogen
influenza
present
studi
investig
potenti
effect
eap
influenza
infect
mous
model
immun
enhanc
effect
innat
immun
recognit
eap
also
evalu
result
suggest
effect
eap
offer
altern
strategi
develop
antiinfluenza
agent
util
e
adenophorum
product
viru
influenza
viru
abarhead
goos
use
studi
isol
qinghai
lake
may
isol
highli
pathogen
poultri
mous
madindarbi
canin
kidney
mdck
cell
viru
propag
mdck
cell
c
h
viral
supernat
harvest
aliquot
store
c
viral
titer
determin
plaqu
assay
describ
previous
anim
cell
femal
balbc
mice
obtain
vital
river
laboratori
beij
china
origin
breed
pair
purchas
charl
river
beij
china
mice
rais
independ
ventil
cage
ivc
receiv
pathogenfre
food
water
anim
treatment
govern
regul
experiment
anim
beij
author
approv
anim
ethic
committe
china
agricultur
univers
mous
leukem
monocyt
macrophag
raw
cell
line
human
lung
adenocarcinoma
epitheli
cell
line
madindarbi
canin
kidney
mdck
cell
line
provid
cell
resourc
center
peke
union
medic
colleg
cell
cultur
maintain
accord
supplier
recommend
yunnan
provinc
china
leav
slice
dri
shade
g
dri
materi
powder
mixer
filter
mesh
leaf
powder
extract
ultrason
treatment
ml
distil
water
min
supernat
collect
precipit
resuspend
ml
distil
water
extract
ultrason
treatment
min
result
supernat
combin
obtain
first
ultrason
treatment
final
aqueou
fraction
evapor
dryness
rotari
evapor
residu
obtain
dissolv
distil
water
kept
frozen
c
extract
centrifug
gmin
min
concentr
c
h
prepar
polysaccharid
supernat
deprotein
use
sevag
method
dialyz
water
h
final
liquid
mix
threefold
volum
ethanol
vv
centrifug
gmin
min
precipit
success
wash
absolut
ethanol
ether
dri
vacuum
c
obtain
crude
polysaccharid
yield
eap
content
determin
phenolh
method
vitro
ml
raw
cell
ml
per
well
plate
plate
cultur
c
co
h
media
remov
ml
cultur
medium
contain
differ
concentr
eap
gml
ad
well
control
treat
phosphatebuff
salin
pb
cell
collect
h
treatment
rna
extract
quantit
polymeras
chain
reaction
qpcr
assay
mice
administr
eap
dose
mgkg
bodi
weight
intranas
daili
day
challeng
control
mice
administ
pb
use
schedul
influenza
viru
stock
dilut
pb
mice
anesthet
zotil
virbac
franc
intramuscularli
mgkg
bodi
weight
infect
intranas
plaqueform
unit
pfu
influenza
viru
l
lung
tissu
five
mice
per
group
collect
day
challeng
qpcr
elisa
lung
tissu
anoth
five
mice
day
postinfect
collect
plaqu
assay
qpcr
ten
mice
per
group
observ
surviv
day
bodi
weight
record
plaqu
assay
mdck
cell
cultur
dmem
hyclon
laboratori
logan
ut
usa
contain
fb
hyclon
laboratori
uml
penicillin
gml
streptomycin
invitrogen
san
diego
ca
usa
lung
tissu
supernat
dilut
ad
cell
monolay
cover
semisolid
agar
contain
gml
trypsin
tpck
sigmaaldrich
st
loui
mo
usa
plate
incub
c
co
h
stain
crystal
violet
total
rna
cell
mg
lung
tissu
prepar
trizol
invitrogen
accord
manufactur
instruct
dnaseitr
rna
g
revers
transcrib
cdna
use
random
primer
express
hemagglutinin
ha
gene
influenza
viru
detect
qpcr
use
power
sybr
green
pcr
master
mix
kit
appli
biosystem
foster
citi
ca
usa
follow
primer
agg
cac
ctc
ctt
aat
gtc
acg
cac
gat
h
cct
tcg
gtc
cag
ttg
cct
cca
gtg
cct
ctt
tgc
tgc
ttt
h
ifn
use
forward
primer
cgc
agt
att
cag
aag
aag
revers
primer
tcc
ata
agg
ata
gac
cag
cta
reaction
run
abi
thermal
cycler
initi
denatur
step
c
min
follow
cycl
c
c
c
copi
number
ha
gene
calcul
softwar
appli
biosystem
use
hacontain
plasmid
known
concentr
standard
rel
qpcr
perform
eight
gene
hactin
h
h
ifn
htnffor
cell
mactin
mmr
mifn
mtnffor
cell
sequenc
primer
shown
tabl
reaction
run
c
min
follow
cycl
denatur
c
sec
anneal
c
extens
c
fold
chang
gene
express
normal
control
naiv
mice
use
actin
intern
standard
elisa
tnf
ifnlevel
lung
test
elisa
kit
boster
wuhan
china
accord
manufactur
protocol
one
gram
lung
tissu
mous
ground
ml
pb
centrifug
min
rpm
supernat
collect
dilut
elisa
statist
analysi
statist
analysi
perform
use
oneway
anova
spss
spss
taiwan
corp
taiwan
consid
signific
mani
botan
polysaccharid
exhibit
immunomodulatori
effect
determin
immunomodulatori
properti
eap
investig
potenti
effect
polysaccharid
cell
cell
treat
variou
concentr
eap
gml
h
mrna
level
tnf
ifnwer
detect
qpcr
figur
show
immunomodulatori
activ
eap
vitro
variou
concentr
eap
trigger
strong
secret
tnf
ifnin
dosedepend
manner
cell
figur
c
cell
figur
f
compar
pb
treatment
group
test
whether
eap
could
protect
infect
mice
mice
treat
eap
dose
mgkg
bodi
weight
intranas
daili
day
prior
viral
challeng
pfu
ten
mice
per
group
monitor
day
surviv
rate
shown
figur
mice
receiv
pb
die
day
mice
administr
mgkg
eap
surviv
rate
day
significantli
higher
receiv
pb
log
rank
analysi
eap
treatment
mgkg
mgkg
also
appear
surviv
advantag
statist
signific
result
suggest
protect
effect
eap
infect
requir
moder
dose
eap
treatment
also
allevi
weight
loss
infect
mice
figur
b
determin
viral
load
lung
infect
mice
plaqu
assay
qpcr
perform
pulmonari
viral
titer
eap
mgkg
group
significantli
lower
titer
mice
receiv
pb
day
postinfect
figur
c
data
clearli
indic
intranas
administr
eap
control
viral
replic
improv
surviv
rate
mous
model
protect
effect
eap
viru
like
due
immunomodulatori
properti
detect
tnf
ifnexpress
lung
five
mice
per
group
collect
day
infect
test
qpcr
elisa
mrna
level
eap
group
mgkg
significantli
higher
pb
control
naiv
mice
figur
c
solubl
cytokin
level
day
measur
elisa
result
consist
qpcr
result
even
though
ifnproduct
eap
group
significantli
higher
pb
group
figur
g
result
suggest
eap
increas
tnf
ifnproduct
tnf
ifnexpress
day
postinfect
determin
qpcr
contrast
tnfmrna
level
follow
eap
mgkg
treatment
significantli
lower
pb
group
figur
e
ifnexpress
slightli
lower
signific
figur
f
result
may
explain
higher
viral
load
sever
inflammatori
respons
pb
treat
mice
excess
inflamm
caus
sever
lung
lesion
influenza
infect
evalu
histopatholog
chang
lung
infect
mice
tissu
group
day
postinfect
examin
lung
pb
treat
mice
exhibit
sever
inflamm
respons
character
interstiti
edema
inflammatori
cellular
infiltr
around
small
blood
vessel
alveolar
lumen
flood
edema
fluid
mix
exfoli
alveolar
epitheli
cell
thicken
alveolar
wall
figur
c
lung
eap
mgkg
treat
mice
exhibit
milder
lesion
receiv
pb
character
sign
bronchopneumonia
interstiti
edema
inflammatori
cell
infiltr
around
small
blood
vessel
figur
b
viral
load
inflammatori
cytokin
product
lung
correl
suggest
eap
treatment
reduc
lung
lesion
infect
mice
polysaccharid
deriv
mani
plant
enhanc
secret
cytokin
chemokin
tnf
immunomodulatori
effect
mediat
mainli
recognit
polysaccharid
polym
sever
pattern
recognit
receptor
prr
determin
receptor
contribut
directli
innat
immun
recognit
eap
tolllik
receptor
mannos
receptor
mr
examin
qpcr
vivo
vitro
mice
treat
eap
dose
mgkg
bodi
weight
intranas
daili
day
control
mice
receiv
pb
lung
total
rna
prepar
qpcr
express
mr
eap
treat
mice
significantli
elev
compar
control
express
slightli
higher
statist
signific
figur
vitro
assay
show
similar
trend
shown
figur
b
cell
treat
gml
epa
h
qpcr
mr
level
significantli
higher
express
chang
data
suggest
eap
recognit
occur
mainli
via
mr
pathway
studi
evalu
immunomodulatori
activ
protect
effect
eap
influenza
infect
mous
model
knowledg
find
first
show
effect
eap
intranas
administr
eap
prior
viral
challeng
improv
surviv
rate
infect
mice
correspond
reduct
pulmonari
viral
load
effect
like
due
innat
immun
recognit
eap
secret
innat
immun
mediat
tnfand
ifn
infect
furthermor
effect
eap
prr
express
includ
mr
determin
vivo
vitro
result
suggest
innat
immun
recognit
eap
depend
upon
activ
mr
pathway
data
demonstr
feasibl
use
eap
novel
immunomodulatori
agent
influenza
infect
unfortun
sugar
composit
eap
character
emerg
new
drugresist
strain
result
antigen
drift
limit
therapeut
benefit
vaccin
antivir
agent
control
influenza
thu
develop
novel
broadspectrum
antiinfluenza
strategi
urgent
need
botan
polysaccharid
ideal
candid
novel
immunomodulatori
agent
due
nontox
properti
fewer
side
effect
compar
bacteri
deriv
polysaccharid
number
polysaccharid
isol
plant
fungi
exhibit
effect
antivir
benefit
influenza
viru
includ
subtyp
use
polysaccharid
immunomodulatori
agent
studi
rare
paper
data
show
immunomodulatori
activ
eap
vivo
vitro
eap
treatment
elev
product
tnf
ifnand
provid
surviv
advantag
infect
mice
surviv
rate
follow
eap
pretreat
mgkg
bodi
weight
significantli
higher
mice
receiv
pb
previou
report
high
level
proinflammatori
cytokin
chemokin
includ
tnf
ifn
detect
infect
cytokin
storm
lead
sever
respiratori
symptom
host
immun
injuri
thu
cytokin
storm
hypothes
main
caus
mortal
use
antiinflammatori
agent
may
therefor
provid
therapeut
effect
howev
unclear
whether
lack
proinflammatori
cytokin
tnfand
facilit
viral
clearanc
interestingli
knockout
evidencebas
complementari
altern
medicin
mice
defici
tnf
tnfreceptor
steroidtr
wildtyp
mice
surviv
advantag
compar
wildtyp
mice
follow
influenza
infect
interestingli
prophylact
treatment
agonist
polyiclc
strongli
upregul
cytokin
product
provid
protect
infect
conflict
studi
may
explain
inflammatori
respons
help
clear
viru
aggrav
host
patholog
damag
elev
product
cytokin
tnf
ifnar
import
viral
clearanc
earli
stage
infect
activ
innat
immun
system
viral
infect
trigger
cytokin
storm
due
high
viral
load
inflammatori
respons
caus
sever
patholog
injuri
even
death
case
receiv
immunomodul
alon
help
anim
surviv
like
explain
immunomodul
treatment
prior
viral
infect
result
better
surviv
rate
studi
treatment
eap
shortli
infect
h
postinfect
provid
surviv
advantag
data
show
antiinfluenza
properti
tnf
ifnhav
discuss
mani
studi
despit
particip
cytokin
storm
trigger
influenza
infect
play
import
role
protect
influenza
viru
requir
viral
clearanc
essenti
anim
surviv
tnfha
report
exert
defens
effect
influenza
infect
vitro
ifntreat
earli
stage
influenza
infect
improv
surviv
rate
mous
model
addit
high
level
ifnsecret
stimul
ginseng
polysaccharid
provid
antiinfluenza
effect
vivo
report
intranas
administr
eap
challeng
elev
express
tnf
ifncompar
mice
receiv
pb
high
level
mediat
contribut
viral
clearanc
antivir
respons
pulmonari
viral
titer
follow
eap
treatment
lower
day
postinfect
contrast
ifnmrna
level
slightli
lower
tnfproduct
significantli
lower
pb
group
regard
excess
inflamm
induc
viru
massiv
secret
mediat
contribut
lung
injuri
rather
antivir
respons
therefor
time
eap
treatment
prophylact
agent
import
immunomodulatori
activ
botan
polysaccharid
thought
mediat
sever
prr
studi
examin
mrna
level
mr
eap
treatment
eap
found
upregul
mr
mrna
express
significantli
vivo
vitro
hypothesi
innat
immun
recognit
eap
driven
mainli
via
mr
depend
pathway
bind
receptor
eap
may
activ
complex
intracellular
signal
pathway
increas
cytokin
product
lead
antivir
respons
thu
protect
eap
treatment
less
like
caus
drug
resist
may
repres
broadspectrum
antiinfluenza
effect
conclus
studi
demonstr
eap
leaf
extract
prophylact
immun
enhanc
agent
influenza
viru
infect
treatment
eap
effect
inhibit
viral
replic
improv
anim
surviv
approach
offer
altern
strategi
antiinfluenza
immunomodulatori
agent
develop
benefit
util
e
adenophorum
product
